Pulmonx Market Capitalization from 2010 to 2025

LUNG Stock  USD 6.97  0.41  5.56%   
Pulmonx Corp's Market Cap is decreasing over the last several years with very volatile swings. Market Cap is predicted to flatten to about 529 M.
Check Pulmonx Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pulmonx Corp's main balance sheet or income statement drivers, such as Interest Expense of 3.9 M, Selling General Administrative of 108.4 M or Total Revenue of 82.9 M, as well as many indicators such as Price To Sales Ratio of 7.7, Dividend Yield of 0.0 or PTB Ratio of 3.87. Pulmonx financial statements analysis is a perfect complement when working with Pulmonx Corp Valuation or Volatility modules.
  
Check out the analysis of Pulmonx Corp Correlation against competitors.
For more detail on how to invest in Pulmonx Stock please use our How to Invest in Pulmonx Corp guide.

Latest Pulmonx Corp's Market Capitalization Growth Pattern

Below is the plot of the Market Cap of Pulmonx Corp over the last few years. It is Pulmonx Corp's Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pulmonx Corp's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 275.23 M10 Years Trend
Very volatile
   Market Cap   
       Timeline  

Pulmonx Market Capitalization Regression Statistics

Arithmetic Mean889,005,237
Geometric Mean799,439,641
Coefficient Of Variation55.05
Mean Deviation293,476,311
Median814,065,994
Standard Deviation489,361,131
Sample Variance239474.3T
Range2.2B
R-Value(0.05)
Mean Square Error255984.4T
R-Squared0
Significance0.86
Slope(4,950,777)
Total Sum of Squares3592114.7T

Pulmonx Market Capitalization History

2025529 M
2024556.8 M
2023484.2 M
2022312.7 M
20211.2 B
20202.5 B
20191.4 B

About Pulmonx Corp Financial Statements

Pulmonx Corp stakeholders use historical fundamental indicators, such as Pulmonx Corp's Market Capitalization, to determine how well the company is positioned to perform in the future. Although Pulmonx Corp investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pulmonx Corp's assets and liabilities are reflected in the revenues and expenses on Pulmonx Corp's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pulmonx Corp. Please read more on our technical analysis and fundamental analysis pages.
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California. Pulmonx Corp operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 253 people.

Currently Active Assets on Macroaxis

When determining whether Pulmonx Corp is a strong investment it is important to analyze Pulmonx Corp's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pulmonx Corp's future performance. For an informed investment choice regarding Pulmonx Stock, refer to the following important reports:
Check out the analysis of Pulmonx Corp Correlation against competitors.
For more detail on how to invest in Pulmonx Stock please use our How to Invest in Pulmonx Corp guide.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmonx Corp. If investors know Pulmonx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmonx Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.47)
Revenue Per Share
2.043
Quarterly Revenue Growth
0.154
Return On Assets
(0.20)
Return On Equity
(0.52)
The market value of Pulmonx Corp is measured differently than its book value, which is the value of Pulmonx that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmonx Corp's value that differs from its market value or its book value, called intrinsic value, which is Pulmonx Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmonx Corp's market value can be influenced by many factors that don't directly affect Pulmonx Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmonx Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmonx Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmonx Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.